Clinical trial
Phase 1/2a, Randomized, Double-Masked, Placebo-Controlled, Multi-center Study Assessing the Safety, Tolerability, And Efficacy Of FM101 In Patients With Ocular Hypertension, And To Assess The Relative Bioavailability Of The FM101 Oral Tablet Formulation In Healthy Participants
NCT04585100 is registered in ClinicalTrials.gov with Future Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1/2a, Randomized, Double-Masked, Placebo-Controlled, Multi-center Study Assessing the Safety, Tolerability, And Efficacy Of FM101 In Patients With Ocular Hypertension, And To Assess The Relative Bioavailability Of The FM101 Oral Tablet Formulation In Healthy Participants
- Lead sponsor
- Future Medicine
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- October 7, 2020
- Completion date
- June 30, 2023
- Enrollment
- 64 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.